Business Context and Reporting Period
This Form 10-Q covers HealthSouth Corporation (filing as HealthSouth, formerly Encompass Health in metadata) for the quarterly period ended September 30, 2006. The company is a major provider of rehabilitative health care, ambulatory surgery, and diagnostic imaging services. During the period, the company announced a strategic shift to explore alternatives for its surgery centers, outpatient, and diagnostic divisions to focus on post-acute care. Additionally, stockholders approved a one-for-five reverse stock split effective October 25, 2006.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Balance Sheet (Sep 30, 2006) |
|---|---|---|---|
| Net Operating Revenues | $731.2 million | $2,281.6 million | N/A |
| Net Loss | $(76.1) million | $(553.7) million | N/A |
| Net Loss Available to Common Shareholders | $(82.6) million | $(569.5) million | N/A |
| Loss Per Share (Basic & Diluted) | $(1.04) | $(7.16) | N/A |
| Operating Cash Flow | N/A | $(75.6) million | N/A |
| Cash and Cash Equivalents | N/A | N/A | $34.2 million |
| Long-Term Debt | N/A | N/A | $3.25 billion |
| Total Assets | N/A | N/A | $3.29 billion |
| Shareholders' Deficit | N/A | N/A | $(2.10) billion |
Material Changes vs. Prior Period
- Revenue Decline: Net operating revenues decreased 4.6% for the quarter and 5.0% for the nine-month period compared to 2005. This was primarily driven by volume declines across all segments due to the 75% Rule phase-in for inpatient facilities, competition, and facility closures.
- Increased Losses: The net loss for the nine months ended September 30, 2006, increased significantly to $553.7 million from $332.2 million in the prior year. This was largely due to a $365.6 million loss on the early extinguishment of debt related to recapitalization transactions in Q1 2006 and a $28.7 million loss on an interest rate swap in Q3.
- Recoveries: The company recorded a $35.0 million recovery of amounts due from former CEO Richard M. Scrushy, which partially offset operating expenses.
- Settlement Expenses: Government, class action, and related settlements expense was $28.4 million for the quarter and $45.7 million for the nine months, compared to $215.0 million in the prior year (which included a large securities litigation settlement charge).
- Debt Restructuring: The company completed recapitalization transactions in March 2006 and a private offering of $1.0 billion in senior notes in June 2006, replacing prior indebtedness with approximately $3 billion of new long-term debt.
Guidance, Outlook, and Risks
- Strategic Repositioning: Management is exploring strategic alternatives, including the spin-off or sale of surgery centers, outpatient, and diagnostic divisions, to focus on the post-acute care sector. Proceeds would be used to deleverage the company.
- Liquidity and Leverage: The company remains highly leveraged with approximately $3.3 billion in long-term debt. While recapitalization improved refinancing risk and operational flexibility, the company faces significant cash obligations for government settlements (Medicare and SEC) totaling approximately $182.8 million remaining through 2007.
- Regulatory Risks: The company faces price pressure from Medicare reimbursement changes (IRF-PPS, ASC pricing caps) and the 75% Rule, which limits non-compliant case volumes. A hold on Medicare payments for the last nine days of the fiscal year impacted cash collections in Q3.
- Legal Contingencies: Significant litigation remains, including securities class actions (preliminary settlement pending court approval), derivative litigation, and disputes with former officers and auditors. The company has accrued liabilities for various settlements but notes that final amounts may vary.
- Internal Controls: Management concluded that disclosure controls and procedures were ineffective as of September 30, 2006, due to material weaknesses in financial reporting that existed as of December 31, 2005, though remediation efforts are ongoing.
Investor Verification Checklist
- Settlement Finality: Verify the status of the $445 million securities litigation settlement and the $325 million Medicare settlement, including court approval dates and final payment schedules.
- Strategic Alternatives: Monitor progress on the sale or spin-off of non-core divisions (surgery, outpatient, diagnostic) and the associated debt reduction plans.
- Debt Covenants: Review compliance with the new Credit Agreement covenants, specifically the leverage ratio (7.50 to 1.00) and interest coverage ratio (1.65 to 1.00), given the high debt load.
- Internal Control Remediation: Assess the timeline and effectiveness of remediation efforts for material weaknesses in internal controls over financial reporting.
- Reimbursement Trends: Evaluate the impact of ongoing Medicare reimbursement changes (IRF-PPS, therapy caps) on future revenue and margins.